IN THE NEWS: Personalized Medicine Evolves With CDK4/6 Inhibitors, Immunotherapy, and ADCs in Breast Cancer

OncLive

Four leading medical oncologists, all members of the Breast Cancer Multidisciplinary Team (MDT) at Barbara Ann Karmanos Cancer Institute, talk about treatments and clinical trials for breast cancer.

• Hadeel Assad, M.D., also member of the Phase I Clinical-Pharmacology MDT, discussed how CDK4/6 inhibitors have been implemented into practice, as well as updates on HER2-positive breast cancer and triple-negative breast cancer clinical trials.
• Lawrence Flaherty, M.D., discussed clinical trails and updates in early and metastatic HER2-positive breast cancer.
• Michael Simon, M.D., MPH, co-leader of the Breast Cancer MDT, discussed treatment evolution of triple-negative breast cancer.
• Jailan Elayoubi, M.D., discussed emerging agents in breast cancer.

Read the full article here.